A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

作者：Mel J R; Salar A; Rodriguez C A; Alegre A; Gonzalez A; Cassinello J; Montesinos J; Gasquet J A; Sanchez J; Saigi E^*

来源：Current Medical Research and Opinion, 2008, 24(10): 2931-2942.

DOI：10.1185/03007990802381323

• Anaemia
• Darbepoetin alfa
• Fatigue
• Multi-cycle chemotherapy

Objective: Anaemia is common in cancer patients treated with chemotherapy. Darbepoetin alfa (DA) is the only erythropoiesis-stimulating protein approved for administration at weekly and every-three-week intervals in cancer patients receiving chemotherapy. This article investigates the effectiveness, tolerability and effect on fatigue of DA.
Methods: Prospective, observational study performed in 30 Spanish centres. Eligible patients were >= 18 years of age, anaemic (haemoglobin [Hb] <= 11 g/dL), with non-myeloid malignancies, receiving chemotherapy. DA (150 mu g) was administered weekly for a maximum of 16 weeks (dosage doubled if Hb increased < 1 g/dL after 4 weeks).
Main outcome measures: Haematopoietic response (Hb increase >= 2 g/dL or Hb >= 12 g/dL in the absence of transfusions in the previous 28 days), transfusion required between Weeks 5 and 16 and fatigue measured by the Fatigue subscale of the Functional Assessment of Cancer Therapy.
Results: 293 adults were recruited (56.4% women), with lymphoproliferative malignancies (44.3%) or solid tumours (55.7%). Baseline Hb was 9-11 g/dL in 83.7% of patients. Sixty-four per cent (95% CI: 58.1-69.4%) had a haematopoietic response and 12% required transfusions. After adjusting for performance status, concomitant diseases and chemotherapy type, an increase in Hb level was significantly associated with an improvement in Fatigue subscale (+1.9 points per 1 g/dL). Only 2% of patients had treatment-related adverse events: thromboembolic pulmonary disease (0.3%); hypersensitivity reaction (0.3%); local pain following DA administration (0.3%); insomnia (0.3%); thrombocytosis (0.3%) and deep vein thrombosis (0.3%).
Conclusions: Fixed-dose DA administered once weekly seems to be an effective, well-tolerated treatment for chemotherapy-induced anaemia in patients with non-myeloid malignancies, and there is an indication of a possible benefit on fatigue in the clinical practice.

• 出版日期2008